Introduction {#sec1}
============

Sepsis results from pus-forming bacteria or virus, and post-inducing endotoxins, in the tissue or blood, and it is associated with an unacceptably high death rate \[[@ref1]\]. The majority of sepsis cases are caused by pneumonia (itself a serious respiratory disorder), and cases can be community-acquired or hospital-acquired \[[@ref2]\]. Although limited data are available regarding sepsis induced by COVID-19, pathogenic coronaviruses-induced sepsis is observed with Middle East respiratory syndrome \[[@ref3]\]. Septic shock is associated with infection-driven systemic immune and organ dysfunction and is characterized by a severe inflammatory response to infection \[[@ref4]\].

![Investigative flowcharts for prioritization of biotargets and signaling pathways of VC action against sepsis through a systematic network pharmacology approach. All the reported genes/targets of VC and sepsis were screened and identified using databases available online prior to harvesting the antisepsis targets of VC. After the construction of a PPI network and identification of the hub targets of VC against sepsis, the biological processes and KEGG signaling pathways were determined. A network of VC-target-GO-KEGG-sepsis was visualized following bioinformatics analysis.](bbaa079f1){#f1}

![The total targets of VC, sepsis and 63 intersection targets of VC action against sepsis were identified via the Venn diagram and PPI network. In the analyses, the inclusion criteria for sepsis targets using DisGeNET and GeneCards databases were identified with gene-disease association score \> 0.1 and gene score \> 1. A PPI network of the 63 targets was plotted following a STRING database with the interaction score set to a high confidence at 0.700.](bbaa079f2){#f2}

![Hub genes/targets of VC action against sepsis were identified as EGFR, MAPK1, JUN and STAT3. In the algorithm using the Cytoscape software, the median and maximum degrees of freedom of the target were 7.055 and 18. The inclusion criteria for the screening of hub targets were set to 15 and 18 for harvesting the four important core targets.](bbaa079f3){#f3}

Common clinical treatments for sepsis aim to reverse dysfunctions of the organ and immune system and include immunomodulating therapies \[[@ref5]\]. In clinical practice, an anti-infection strategy using antibacterials is prescribed to manage sepsis \[[@ref6]\]. However, the chemotherapeutics (including antibacterial agents, antiviral drugs) used for antisepsis have been linked with adverse reactions \[[@ref7], [@ref8]\]. As a result, there is an express need for pharmacologically bioactive components that combat sepsis.

Vitamin C (VC) is a key trace element with known beneficial effects, including antioxidation effects, antiaging effects and the prevention of angiocardiopathy \[[@ref9]\]. Interestingly, VC treatment was found to elevate the survival rate of septic patients in an intensive care unit \[[@ref10]\]. Moreover, VC has been reported to be an alternative therapeutic agent against sepsis \[[@ref11]\]. Clinical investigations have revealed that high doses of intravenous VC may reduce inflammation and vascular injury related to sepsis \[[@ref12]\]. VC has several known pharmacological actions, and VC therapy may reduce inflammatory reaction, oxidative stress and ameliorate endovascular and immunologic dysfunctions \[[@ref13]\].

Generally, data reporting the use of VC against sepsis have been collected from preliminary clinical investigations, and in-depth mechanistic preclinical studies are currently limited. In addition, details of biomarkers and the signaling pathways through which VC exerts its effects against sepsis remain unknown. A network pharmacology-based approach has previously proved successful in revealing treatable targets and mechanisms from bioinformatics assays \[[@ref14]\]. Indeed, in our previous studies, we have identified the pharmacological biotargets of several bioactive agents used to manage clinical diseases \[[@ref15], [@ref16]\].

Accordingly, our present study was designed to use this emerging network pharmacology approach to reveal predictive targets and therapeutic mechanisms underlying the action of VC against sepsis. We hope that the predictive targets and therapeutic mechanisms may be subsequently verified in *in vitro* and *in vivo* experiments.

![Biological process (BP) from bioinformatics data showing the top 20 BPs of VC action against sepsis. With the use of R-language packages, the four core targets were reassayed for GO-based biological function enrichment. (A) The blue Circro circles show the genes enriched in the top 10 items, and a total of top 10 BP enrichment items. (B) The bubble diagram shows the top 20 BP enrichment data. The *x*-axis represents the gene ratio and the intensities of different colors represent the adjusted *P*-value. (C) The histograms show the top 20 BP enrichment results. The *x*-axis represents the enriched gene count and the intensities of different colors represent the adjusted *P*-value.](bbaa079f4){#f4}

![Detailed molecular pathways from bioinformatics findings exhibited the top 20 KEGG pathways of VC action against sepsis. Using the R-language packages, the four core targets were reanalyzed to reveal the KEGG molecular pathways. (A) The blue Circro circles show the genes enriched in the top 10 KEGG items. (B) The bubble diagram shows the top 20 KEGG enrichment pathways; the *x*-axis represents the gene ratio and the intensities of different colors represent the adjusted *P*-value. (C) The histograms highlight the top 20 KEGG enrichment pathways. The *x*-axis represents the enriched gene count and the intensities of different colors represent the adjusted *P*-value.](bbaa079f5){#f5}

![Network visualization from bioinformatics analysis highlighting the detailed interactions of VC-target-GO-KEGG-sepsis. The pink ovals represent the top 20 biological processes (pharmacological activities) in the action of VC against sepsis, and the yellow diamonds represent the top 20 KEGG signaling pathways (pharmacological mechanisms) in the action of VC against sepsis.](bbaa079f6){#f6}

Methods {#sec2}
=======

Screening of antiseptic targets of VC {#sec3}
-------------------------------------

Using the Traditional Chinese Medicine Systems Pharmacology (TCMSP) \[[@ref17]\], Drugbank \[[@ref18]\], SuperPred \[[@ref19]\] and Swiss Target Prediction \[[@ref20]\] databases, well-reported pharmacological targets of VC were obtained. Likewise, the DisGeNET \[[@ref21]\], Drugbank, and Genecard \[[@ref22]\] databases were used to screen pathological targets of sepsis. All primary targets of VC and sepsis were evaluated using Venn diagrams to identify potential targets for VC against sepsis \[[@ref23]\].

Screening of best targets of VC against sepsis and construction of interrelated network {#sec4}
---------------------------------------------------------------------------------------

Using a STRING database, the mapped target of VC action against sepsis were reassayed to harvest a target-to-target function-related protein network, protein--protein interaction (PPI) network, and tsv. data. Furthermore, NetworkAnalyzer in Cytoscape_v3.7.1 was used to analyze topology parameters, such as median degrees of freedom and maximum degrees of freedom, in the network \[[@ref24]\]. The best targets were selected based on degree values, with the upper limit of the filtering range taken as the maximum degree-value in the topology data and the lower limit taken as twice the median of freedom \[[@ref25]\].

Assays of functional processes and molecular pathways {#sec5}
-----------------------------------------------------

The R packages of 'ClusterProfiler', 'ReactomePA' and 'AnnotationHub' were used for enrichment analysis of Gene Ontology (GO) in biological function (BP) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway using the previously identified best targets. This data were used to generate a corresponding bubble chart and histogram \[[@ref26]\]. GO and KEGG analyses were performed using clusterProfiler (version 3.14.3) \[[@ref27]\] and ReactomePA (version 1.30.0) \[[@ref28]\] from the R packages. GO data were acquired from [org.Hs.eg](http://org.Hs.eg).Db using a cut-off value adjusted to *P* \< 0.05.

Visualization of network relationships {#sec6}
--------------------------------------

By using Cytoscape_v3.7.1 software, the targets of VC action against pneumonia and other best targets were enriched for KEGG-GENE visualization to facilitate further data analysis \[[@ref29]\].

Results {#sec7}
=======

A bioinformatics diagram of the target-based prioritization through systematic pharmacology approach that was used to help identify the VC action against sepsis is shown in [Figure 1](#f1){ref-type="fig"}.

Detailed data of targets and PPI network {#sec8}
----------------------------------------

The inclusion criteria for sepsis screening through DisGeNET database was a gene-disease association score \> 0.1 and for sepsis screening through GeneCards database was a gene score \> 1. Using these criteria, 1704 genes associated with sepsis were identified. VC drug targets were screened and identified through both the TCMSP and Swiss Target Prediction databases, and 161 VC targets were identified (after removing duplicates) using Uniprot database. A Venn diagram of the two target sets was then used to obtain 63 intersection targets ([Figure 2](#f2){ref-type="fig"}). Using a minimum required interaction score set to 0.700 (high confidence), a STRING database was used to collect function-related PPI data from the 63 targets ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}). The pharmacological targets of VC action against sepsis and function-related PPI network was then constructed ([Figure 2](#f2){ref-type="fig"}).

P‌PI network topology parameters and best core targets {#sec9}
------------------------------------------------------

The mapped proteins were imported into Cytoscape software to calculate the topological parameters of the interaction network of VC against sepsis targets and function-related proteins. The median degree of freedom of the target was 7.055 and the maximum degree of freedom was 18. The inclusion criteria for the core target screening conditions were set to 15 and 18 to obtain the optimal four core targets. These were epidermal growth factor receptor (EGFR), mitogen-activated protein kinase-1 (MAPK1), proto-oncogene c (JUN) and signal transducer and activator of transcription-3 (STAT3) ([Figure 3](#f3){ref-type="fig"}).

Core targets in GO BPs and KEGG pathway enrichment {#sec10}
--------------------------------------------------

Using R language-related packages, the four core targets were analyzed for GO BP enrichment and by KEGG pathway analysis. The results of these analyses were visualized using a GO BP bubble diagram and histogram ([Figure 4**A**](#f4){ref-type="fig"}--**C**), and an enriched in KEGG pathways bubble diagram and histogram ([Figure 5**A**](#f5){ref-type="fig"}--**C**). According to the findings, GO BPs related to these targets included regulation of muscle cell proliferation; cellular response to cadmium ion; response to cadmium ion; epithelial cell proliferation; astrocyte differentiation; eyelid development in camera-type eye; cellular response to reactive oxygen species; cellular response to metal ion; positive regulation of epithelial cell proliferation; cellular response to inorganic substance; glial cell differentiation; positive regulation of DNA metabolic process; response to reactive oxygen species; positive regulation of gene silencing by micro RNA (miRNA); positive regulation of posttranscriptional gene silencing; learning or memory, gliogenesis; cognition; positive regulation of pre-miRNA transcription by RNA polymerase II; and cellular response to oxidative stress. Other related BPs are listed in [Supplementary Table 2](#sup2){ref-type="supplementary-material"}. The KEGG 90 pathways related to these targets (*P* \< 0.05) included programmed death-ligand 1 (PD-L1) expression and PD-1 checkpoint pathway in cancer; non--small-cell lung cancer; pancreatic cancer; EGFR tyrosine kinase inhibitor resistance; ErbB signaling pathway; colorectal cancer; GnRH signaling pathway; endocrine resistance; choline metabolism in cancer; AGE-RAGE signaling pathway in diabetic complications; Th17 cell differentiation; HIF-1 signaling pathway; relaxin signaling pathway; FOXO signaling pathway; estrogen signaling pathway; breast cancer; oxytocin signaling pathway; Hepatitis C; Hepatitis B; and Kaposi sarcoma-associated herpesvirus infection. Other related pathways are listed in [Supplementary Table 3](#sup3){ref-type="supplementary-material"}.

Construction of network diagram {#sec11}
-------------------------------

Using Cytoscape software, a network visualization of VC against sepsis targets and an interaction diagram for core target-related pathways were generated ([Figure 6](#f6){ref-type="fig"}). Additional hub genes from interlaced networks identified through KEGG Mapper assays were highlighted in red ([Supplementary Figure S1](#sup4){ref-type="supplementary-material"}).

Discussion {#sec12}
==========

Sepsis is the main cause of infection-associated death and therefore a healthcare priority \[[@ref30]\]. The potential clinical pathogenesis of sepsis includes oxidative stress, immune dysfunction and inflammatory infiltration \[[@ref31]\]. In the early stages of sepsis, an excessive immunological reaction leads to immune dysfunction, leaving the patient susceptible to secondary infections \[[@ref32]\]. As the pathogenesis of sepsis is related to immune dysfunction and inflammatory stress, potential agents with antisepsis activities should target these processes. As mentioned above, clinical findings suggest that supplemental VC may reduce infection risks, including those associated with human sepsis \[[@ref33]\]. However, the antisepsis therapeutic mechanism exerted by VC has not been characterized. The use of systematic network pharmacology for the identification and optimization of screening biotargets, functional processes, and molecular pathways of VC action against sepsis is an attractive research approach that can be completed before any future preclinical or clinical research. Using a promising bioinformatics assay, all potential biotargets of VC action against sepsis were methodically obtained, and the potential core pharmacological targets were identified as EGFR, MAPK1, JUN and STAT3. Functionally, EGFR activation can induce the proliferation of epithelial cells through regulation of the FOXO signaling pathway \[[@ref34]\]. Some evidences indicate that suppression of the EGFR pathway via the reduction of eIF2α phosphorylation increases susceptibility to cellular oxidative stress \[[@ref35]\]. It was also revealed in a clinical study that patients with EGFR mutation had increased PD-L1 expression and T cell infiltration \[[@ref36]\]. The other identified core target, MAPK1, was responsible for the proliferation and survival of epithelial cells \[[@ref37]\]. Increased activity of MAPK1 was reported to induce the survival of dendritic cells through the suppression of PD-1 expression \[[@ref38]\]. In contrast, inhibition of Jun also reduced the proliferation and transition of epithelial cells \[[@ref39]\]. In addition, activation of Jun expression could induce the activity of PD-L1 via glutamine depletion \[[@ref40]\]. Other evidences also suggest that the activation of STAT3 is positively correlated with PD-L1 expression in inducing of the development of lymphoma \[[@ref41]\]. Moreover, it has been reported that STAT3 promotes the proliferation of epithelial cells through the suppression of Krüppel-like factor 4 (KLF4) \[[@ref42]\], and mediates oxidative stress in the lysosomal system \[[@ref43]\]. Our bioinformatics analysis clearly showed that the four identified core targets might beneficially suppress sepsis-associated epithelial cell necrosis or apoptosis in the lung, peritoneum and bile duct. Furthermore, VC-mediated antioxidative effect might contribute to the reduction in the release of inflammatory cytokines and sepsis-related inflammatory reaction. In future investigations, we intend to elucidate the pharmacological mechanisms underlying the action of VC against sepsis through the modulation of EGFR, MAPK1, JUN and STAT3.

In network pharmacology analysis, additional bioinformatics findings from GO annotation and KEGG analysis revealed that the potential VC antisepsis effects were mechanistically linked to pharmacological modulation of epithelial cell proliferation, cellular response to oxidative stress, immune dysfunction and inflammatory stress. From the detailed bioinformatics data, analysis of the molecular mechanisms correlated with VC action against sepsis suggests that VC action against sepsis is pharmacologically achieved via the regulation of EGFR tyrosine kinase inhibitor resistance pathway, and ErbB, GnRH and FOXO signaling pathways, as well as through the inactivation of intrapulmonary Th17 cell differentiation, the Th1 and Th2 cell differentiation pathways, the B cell receptor signaling pathway, the Toll-like receptor signaling pathway, IL-17 signaling pathways and TNF signaling pathways.

Immunological dysfunction is a disease condition where the immune system fails in its normally physiological action. Pathologically, immunological dysfunction can be associated with existing clinical diseases, such as allergy, acquired immune deficiency syndrome and rheumatism \[[@ref44]\]. It has been reported that the changes to the innate and adaptive immune responses that occur during sepsis are a lasting development, and that immune-modulatory treatment is necessary \[[@ref45]\]. The main pathogenesis of sepsis is a cytokine 'storm' induced by an autoamplifying inflammatory mediator such as IL-17 or TNF-α \[[@ref46]\]. Together, the bioinformatics findings we have harvested hint that the specific inactivation of molecular pathways of immune dysfunction and inflammatory stress and targeted modulation of intrapulmonary EGFR, MAPK1, JUN and STAT3 expressions, may be potential pathways of VC action against sepsis. In future clinical practice, chemotherapeutics, including inflammation-based inhibitors and immunomodulators, may enhance the therapeutic effectiveness and reduce the side effects of VC supplementation during the management of sepsis.

Conclusion {#sec13}
==========

Overall, our bioinformatics approach of using network pharmacology has effectively highlighted potential therapeutic targets, BPs and pharmacological pathways of VC action against sepsis. The bioinformatics data presented identify potential targets that may be validated in a preclinical study before being used for the clinical treatment of sepsis with VC.

Key Points {#sec16}
----------

Network pharmacology analysis is a potent approach for untangling all potential biotargets and signaling pathways of agents used to treat clinical diseases.All antisepsis biotargets exerted by vitamin C were identified by systematic pharmacology.The most important biotargets of vitamin C against sepsis were identified accordingly.The top biological processes and molecular pathways of vitamin C action against sepsis were screened and highlighted.Vitamin C may be a potent agent for treating clinical sepsis according to our bioinformatics findings.
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